Immuneering

What Immuneering does

Immuneering Corporation is a Cambridge, Massachusetts-based clinical-stage oncology company developing Deep Cyclic Inhibitors, a proprietary class of MEK inhibitors designed to disrupt tumor adaptation through rhythmic dosing that delivers strong MEK inhibition followed by a short recovery window, repeating daily. The lead candidate atebimetinib (IMM-1-104) is an oral, once-daily Deep Cyclic Inhibitor in pivotal Phase 3 development (MAPKeeper 301) for first-line metastatic pancreatic cancer in combination with modified gemcitabine/nab-paclitaxel, and in Phase 2 development for RAS-mutant non-small cell lung cancer in combination with Regeneron's Libtayo and Eli Lilly's olomorasib. A second Deep Cyclic Inhibitor, envometinib (IMM-6-415), completed Phase 1/2a in April 2025 and is positioned as a Phase 2-ready partnering asset. Phase 2a data showed a 17.3-month median overall survival in 55 first-line pancreatic cancer patients versus an 8.5-month historical benchmark, with ctDNA analysis from 123 patients demonstrating rare acquired resistance mutations.

The company is pre-revenue and reports no product sales; it monetizes only through future drug commercialization or potential partnering transactions. As of Q1 2026, Immuneering held approximately $198.6 million in cash, cash equivalents, and marketable securities with runway into 2029, following a ~$225 million September 2025 public offering and a $25 million August 2025 private placement led by Sanofi. With 51–100 employees, FDA and EMA Phase 3 alignment secured, Nasdaq Biotechnology Index inclusion (December 2025), and a market capitalization of approximately $309–359 million, the company is positioning for its first pivotal readout (topline mid-2028) and eventual commercial launch in pancreatic cancer. The business model is the standard clinical-stage biotech path: build clinical evidence through Phase 2/3 trials, establish credibility via ASCO/AACR presentations and peer-reviewed publications, secure KOL engagement, and pursue either direct specialty-pharmacy commercialization or co-development/co-commercialization partnerships with large pharma counterparties such as Sanofi, Regeneron, and Eli Lilly.

Name

Immuneering

Legal name

Immuneering Corporation

Website

https://immuneering.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Immuneering is a clinical-stage oncology company developing Deep Cyclic Inhibitors — a proprietary class of MEK inhibitors — with lead drug atebimetinib in pivotal Phase 3 for first-line pancreatic cancer and Phase 2 for RAS-mutant NSCLC, targeting cancer patients with limited treatment options.

Ownership category

akta.pro rank

Product category

Clinical-stage Oncology Therapeutics

NAICS

Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

akta.pro secondary industries

CAR-T & TCR-T Therapies (HLAAABAC), NK Cell Therapies (HLAAABAD)

Keywords

• Clinical-stage oncology
• MEK inhibitor development
• MAPK pathway therapies
• Targeted cancer therapeutics
• Oncology drug pipeline

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company. The company is developing oncology drugs (atebimetinib, envometinib) targeting MAPK-driven cancers. No commercial products yet; all candidates are in clinical trials. Future revenue will come from drug sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Immuneering develops Deep Cyclic Inhibitors, a proprietary class of MEK inhibitors that deliver pulsed drug exposure to outpace tumor adaptive resistance. Its lead clinical asset atebimetinib (IMM-1-104) is being evaluated in the global Phase 3 MAPKeeper 301 trial for first-line metastatic pancreatic cancer and in Phase 2 for RAS-mutant non-small cell lung cancer, while envometinib (IMM-6-415) is a Phase 2-ready second asset.

Product overview

Immuneering is a clinical-stage oncology company developing Deep Cyclic Inhibitors, a novel class of targeted cancer therapies. The company's lead product is atebimetinib (IMM-1-104), an oral, once-daily MEK inhibitor that uses rhythmic pulsing to disrupt tumor adaptation while allowing healthy cells to recover. Atebimetinib is in Phase 3 development (MAPKeeper 301) for first-line pancreatic cancer and Phase 2 for lung cancer. The second product, envometinib (IMM-6-415), is a twice-daily Deep Cyclic Inhibitor that completed Phase 1 in 2025 and is available for partnering.

Differentiator

Problem solved

Functional benefit

Brands

• Deep Cyclic Inhibitors: A new class of targeted therapies designed to minimize cumulative toxicities, disrupt cancer's rapid adaptive behaviors, and reduce resistance while enabling longer-lasting therapeutic benefit.

Products and services

• Atebimetinib (IMM-1-104) Oral, once-daily Deep Cyclic Inhibitor of MEK in late-stage clinical trials for first-line pancreatic cancer and non-small cell lung cancer. Designed to target RAS, RAF, and MAPK pathway-driven cancers with greater durability and tolerability through a rhythmic pulsing approach.
• Envometinib (IMM-6-415) Oral, twice-daily Deep Cyclic Inhibitor of MEK. Phase 1/2a trial completed in April 2025 in patients with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations. Phase 2-ready asset available for partnering.
• MAPKeeper 301 Phase 3 Trial Global pivotal Phase 3 clinical trial evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic adenocarcinoma. Expected enrollment of approximately 510 patients with topline results expected mid-2028.

Quantifiable outcome

• 64% overall survival at 12 months (vs 35% historical benchmark) in first-line pancreatic cancer patients treated with atebimetinib plus mGnP
• +5 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• Regeneron PharmaceuticalscoreTechnology or IntegrationImmuneering and Regeneron established a clinical supply agreement to evaluate atebimetinib (IMM-1-104) in combination with Libtayo (cemiplimab), Regeneron's FDA-approved PD-1 checkpoint inhibitor, with or without chemotherapy, in patients with first-line metastatic RAS-mutant non-small cell lung cancer. First patient dosing expected in 2H 2026.
• Eli Lilly and CompanycoreTechnology or IntegrationImmuneering and Lilly established a clinical supply agreement to evaluate atebimetinib (IMM-1-104) in combination with olomorasib (Lilly's KRAS G12C inhibitor) in patients with KRAS G12C-mutant non-small cell lung cancer.
• PanCAN (Pancreatic Cancer Action Network)supportingOthersImmuneering supports PanCAN as a Scientific & Medical Industry Champion, aligning with the company's goal to help people with pancreatic cancer live longer and feel better through participation in patient advocacy and awareness initiatives.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Revolution Medicines: Clinical-stage oncology company developing RAS(ON) inhibitors targeting RAS-driven cancers, including pancreatic cancer and NSCLC. Most directly comparable peer given shared focus on inhibiting the MAPK pathway in RAS-mutant tumors with novel mechanism approaches.
• Erasca: Precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, including pan-RAS and pan-RAF inhibitors. Closely aligned in mission and target biology with Immuneering's MEK Deep Cyclic Inhibition approach.
• Mirati Therapeutics: Developed Krazati (adagrasib), a KRAS G12C inhibitor approved for NSCLC, and was acquired by Bristol-Myers Squibb in 2024 for ~$4.8B. Directly comparable as a RAS-targeted oncology company in the same therapeutic space as Immuneering.
• Relay Therapeutics: Clinical-stage precision oncology company developing small molecule therapies targeting driver mutations in cancer, including RAS-driven tumors. Comparable as a small-molecule precision oncology peer with similar development-stage profile.
• Black Diamond Therapeutics: Precision oncology company developing small molecule kinase inhibitors against allosteric and oncogenic driver mutations, including in the MAPK pathway. Comparable in scale, stage, and approach to Immuneering.

Emerging players

• Day One Biopharmaceuticals: Clinical and commercial-stage oncology company developing targeted therapies for genomically defined cancers, including pediatric and adult tumors. Comparable as a small-molecule targeted oncology peer with a focus on rare/genomically defined indications.
• Foghorn Therapeutics: Clinical-stage biotechnology company developing medicines targeting the chromatin regulatory system in cancer. Comparable as a precision oncology platform company of similar size and stage, with oncology focus but distinct mechanism.
• Cogent Biosciences: Clinical-stage biotechnology company developing precision therapies for genetically defined diseases, including oncology. Comparable as a small-cap precision oncology peer of similar size and clinical stage.
• Zentalis Pharmaceuticals: Clinical-stage small molecule oncology company developing a pipeline of targeted cancer therapies. Notable comparable because Diana Hausman, an Immuneering board member, was formerly CMO at Zentalis, indicating direct familiarity with the company's profile.

Others

• Array BioPharma: Acquired by Pfizer in 2019 for ~$11.4B; developed Mekinist (trametinib) and Braftovi (encorafenib), approved MEK and BRAF inhibitors widely used in melanoma and other MAPK-driven cancers. Relevant precedent for what a successful MEK inhibitor franchise can look like at scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/immuneering
• LinkedInlinkedin.com/company/immuneering-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immuneering